Nuveen, LLC Galectin Therapeutics Inc Call Options Transaction History
Nuveen, LLC
- $315 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GALT
# of Institutions
117Shares Held
10.2MCall Options Held
3.78MPut Options Held
5.27M-
Vanguard Group Inc Valley Forge, PA2.19MShares$2.83 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.02 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$1.58 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA853KShares$1.1 Million0.0% of portfolio
-
Geneos Wealth Management Inc.427KShares$551,3910.01% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $76.7M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...